期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 27, 期 32, 页码 5376-5391出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v27.i32.5376
关键词
Immunotherapy; Immune checkpoint inhibitors; Hepatitis; Adverse drug event; Drug-induced liver injury; Immunosuppression
The use of immune checkpoint inhibitors in cancer treatment has advanced significantly, but adverse events such as immune checkpoint inhibitor-related hepatotoxicity can occur and require prompt investigation and management.
The application of immune checkpoint inhibitors (ICI) in advanced cancer has been a major development in the last decade. The indications for ICIs are constantly expanding into new territory across different cancers, disease stages and lines of therapy. With this increased use, adverse events including immune checkpoint inhibitor-related hepatotoxicity (ICH) have emerged as an important clinical problem. This along with the introduction of ICI as first- and second-line treatments for advanced hepatocellular carcinoma makes ICH very relevant to gastroenterologists and hepatologists. The incidence of ICH varies between 1%-20% depending on the number, type and dose of ICI received. Investigation and management generally involve excluding differential diagnoses and following a stepwise escalation of withholding or ceasing ICI, corticosteroid treatment and adding other immunosuppressive agents depending on the severity of toxicity. The majority of patients with ICH recover and some may even safely recommence ICI therapy. Guideline recommendations are largely based on evidence derived from retrospective case series which highlights a priority for future research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据